How much did Keros Therapeutics, Inc. raise?

Keros Therapeutics, Inc. raised $11.5 Million in a funding round on November 21, 2018.

Who are the decision-makers at Keros Therapeutics, Inc?

Fundz holds 1 contact at Keros Therapeutics, Inc., including the Director Head of Medical Writing. Names and contact details are shown to Fundz members.

Keros Therapeutics, Inc. reported raising $11.5 Million in an initial SEC Form D filing, from an offering of $23 Million

PUBLIC · KROSNov 21, 2018$11.5M of $23M raised

Amount Raised

$11.5 Million

$11.5 Million sold, per SEC Form D (first sale Nov 21, 2018)

Round Type

Venture

LexingtonBiotechnology

Quick answer

Keros Therapeutics, Inc. raised $11.5 Million in a funding round, dated November 21, 2018. Keros Therapeutics, Inc. is based in Lexington, South Carolina, United States.

How much did Keros Therapeutics, Inc. raise?: Keros Therapeutics, Inc. raised $11.5 Million in a funding round on November 21, 2018.
What does Keros Therapeutics, Inc. do?: Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß..
Where is Keros Therapeutics, Inc. based and how big is it?: Keros Therapeutics, Inc. is based in Lexington, South Carolina, United States.
Who are the decision-makers at Keros Therapeutics, Inc?: Fundz holds 1 contact at Keros Therapeutics, Inc., including the Director Head of Medical Writing. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Keros Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

Pear Therapeutics, Inc. raised $64M on January 4, 2019.
NeuroOne Medical Technologies Corporation raised $400K (Seed) on January 4, 2019.
Cardio Flow, Inc. raised an undisclosed amount on January 4, 2019.
REPLICATE Dental Technologies PLC raised an undisclosed amount on January 4, 2019.
Banyan Biomarkers, Inc. raised $2.2M (Seed) on January 4, 2019.
Cardiol Therapeutics Inc. raised $3.7M (Seed) on January 4, 2019.

Who to call at Keros Therapeutics, Inc., and when

A new round usually means Keros Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Keros Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Keros Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Keros Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Keros Therapeutics, Inc.

Location

99 HAYDEN AVENUE

Lexington, South Carolina, United States

About

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing large and small molecules that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead protein therapeutic product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF. Keros’ second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Keros Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

1 contact

Verified contactsJoanne, Director Head of Medical WritingSee plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for Keros Therapeutics, Inc.'s next move

See what Strategic adds

Keros Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.